Revance Therapeutics soars after Crown Labs raises offer to $3.65 a share
Revance Therapeutics (NASDAQ:RVNC) jumped 11% in premarket trading after Crown Laboratories increased its offer above Teoxane's latest bid. Crown Labs increased its offer to $3.65 a share, above ...
Crown Labs Proposed Higher Revance Bid to Save Deal
Crown Laboratories plans to raise its takeover price for Revance Therapeutics to $3.65 a share, topping a rival $3.60-a-share bid from Swiss medical-aesthetics company Teoxane.
Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr
Crown Laboratories and Revance Therapeutics (RVNC) announced that, on January 17, 2025, they amended their previously announced ...